Author Page for Christopher M. Holman

1.

The Impact of Human Gene Patents on Innovation and Access: A Survey of Human Gene Patent Litigation

UMKC Law Review, Vol. 76, p. 295, 2007

Number of pages: 67 Posted: 11 Feb 2008 Last Revised: 26 Mar 2013

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 1,766 (16,556)

Abstract:

2.

Is Lilly Written Description a Paper Tiger?: A Comprehensive Assessment of the Impact of Eli Lilly and its Progeny in the Courts and Pto

Albany Law Journal of Science and Technology, Vol. 17, 2007

Number of pages: 93 Posted: 18 Oct 2006

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 707 (61,692)

Citation 3

Abstract:

3.

Do Reverse Payment Settlements Violate the Antitrust Laws?

Santa Clara Computer and High Technology Law Journal, Vol. 23, p. 489, 2007

Number of pages: 99 Posted: 30 May 2007

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 567 (81,529)

Abstract:

4.

Will Gene Patents Derail the Next-Generation of Genetic Technologies?: A Reassessment of the Evidence Suggests Not

80 UMKC L. REV. 563 (2012).

Number of pages: 44 Posted: 08 Feb 2012 Last Revised: 05 Apr 2013

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 431 (113,939)

Citation 4

Abstract:

5.

Gene Patents Under Fire: Weighing the Costs and Benefits

Christopher M. Holman, Gene Patents under Fire: Weighing the Costs and Benefits, book chapter in BIOTECHNOLOGY AND SOFTWARE PATENT LAW: A COMPARATIVE REVIEW ON NEW DEVELOPMENTS, edited by Emanuela Arezzo and Gustavo Ghidini, Edward Elgar Publishing (2011).

Number of pages: 28 Posted: 17 Nov 2010 Last Revised: 18 Feb 2015

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 401 (123,574)

Abstract:

6.

Bilski: Assessing the Impact of a Newly Invigorated Patent Eligibility Doctrine on the Pharmaceutical Industry and the Future of Personalized Medicine

Christopher M. Holman, Bilski: Assessing the Impact of a Newly Invigorated Patent-Eligibility Doctrine on the Pharmaceutical Industry and the Future of Personalized Medicine, 10 CURRENT TOPICS IN MEDICINAL CHEMISTRY 1937 (2010).

Number of pages: 13 Posted: 23 Jun 2009 Last Revised: 18 Feb 2015

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 381 (130,999)

Abstract:

7.

Copyright for Engineered DNA: An Idea Whose Time Has Come?

Christopher M. Holman, Copyright for Engineered DNA: An Idea Whose Time Has Come, 113 W. VA. L. REV. 699 (2011).

Number of pages: 40 Posted: 17 Nov 2010 Last Revised: 18 Feb 2015

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 357 (140,835)

Citation 5

Abstract:

8.

Protein Similarity Score: A Simplified Version of the Blast Score as a Superior Alternative to Percent Identity for Claiming Genuses of Related Protein Sequences

Santa Clara Computer & High Technology Law Journal, Vol. 21, p. 55, 2004

Number of pages: 45 Posted: 01 Oct 2006

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 355 (141,697)

Abstract:

9.

Will Gene Patents Impede Whole Genome Sequencing?: Deconstructing the Myth that 20% o the Human Genome Is Patented

Christopher M. Holman, Will Gene Patents Impede Whole Genome Sequencing?: Deconstructing the Myth That 20% of the Human Genome Is Patented, 2 IP THEORY 1 (2011).

Number of pages: 15 Posted: 25 Jul 2011 Last Revised: 18 Feb 2015

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 312 (163,126)

Citation 2

Abstract:

10.

Biotechnology's Prescription for Patent Reform

Review of Intellectual Property Law, Vol. 5, p. 318, 2006

Number of pages: 31 Posted: 22 Sep 2006

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 295 (172,500)

Abstract:

11.

Antibody Patents: Use of the Written Description and Enablement Requirements at the Patent & Trademark Office

Berkeley Technology Law Journal, Forthcoming, WVU College of Law Research Paper No. 2022-005

Number of pages: 52 Posted: 10 Feb 2022 Last Revised: 22 Feb 2023

S. Sean Tu and Christopher M. Holman

West Virginia University College of Law and University of Missouri - Kansas City School of Law

Downloads 285 (178,886)

Abstract:

12.

Recent Developments Affecting the Enforcement, Procurement, and Licensing of Research Tool Patents

Joshua D. Sarnoff & Christopher M. Holman, Recent Developments Affecting the Enforcement, Procurement, and Licensing of Research Tool Patents, 23 BERKELEY TECH. L.J. 1299 (2008).

Number of pages: 68 Posted: 10 Apr 2008 Last Revised: 18 Feb 2015

Joshua D. Sarnoff and Christopher M. Holman

DePaul University College of Law and University of Missouri - Kansas City School of Law

Downloads 255 (200,013)

Citation 2

Abstract:

13.

Antibody Claims and the Evolution of the Written Description / Enablement Requirement

IDEA 63(1):84 (2023)

Number of pages: 54 Posted: 07 Dec 2022 Last Revised: 14 Jan 2023

S. Sean Tu and Christopher M. Holman

West Virginia University College of Law and University of Missouri - Kansas City School of Law

Downloads 250 (203,975)

Citation 1

Abstract:

14.

Learning from Litigation: What Can Lawsuits Teach Us About the Role of Human Gene Patents in Research and Innovation?

Kansas Journal of Law & Public Policy, Vol. 18, p. 215, 2009

Number of pages: 52 Posted: 01 Sep 2009 Last Revised: 30 Mar 2013

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 226 (225,873)

Abstract:

15.

In Defense of Secondary Pharmaceutical Patents: A Response to the UN's Guidelines for Pharmaceutical Patent Examination

Indiana Law Review, Forthcoming

Number of pages: 56 Posted: 04 Sep 2016

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 217 (233,697)

Citation 2

Abstract:

16.

Response to ‘Pervasive Sequence Patents Cover the Entire Human Genome’

Genome Medicine, Vol. 6, No. 14, 2014, George Mason Law & Economics Research Paper No. 14-07, San Diego Legal Studies Paper No. 14-148, Loyola-LA Legal Studies Paper No. 2014-19, Georgia State University College of Law, Legal Studies Research Paper No. 2014-16

Number of pages: 4 Posted: 01 Mar 2014 Last Revised: 14 May 2014

S. Sean Tu, Christopher M. Holman, Adam Mossoff, Ted M. Sichelman, Michael Risch, Jorge L. Contreras, Yaniv Heled, Gregory Dolin and Lee Petherbridge

West Virginia University College of Law, University of Missouri - Kansas City School of Law, George Mason University - Antonin Scalia Law School, University of San Diego School of Law, Villanova University Charles Widger School of Law, University of Utah - S.J. Quinney College of Law, Georgia State University College of Law, University of Baltimore - School of Law and Loyola Law School Los Angeles

Downloads 197 (255,361)

Citation 1

Abstract:

17.

Mayo, Myriad, and the Future of Innovation in Molecular Diagnostics and Personalized Medicine

Christopher M. Holman, Mayo, Myriad, and the Future of Innovation in Molecular Diagnostics and Personalized Medicine, 15 North Carolina Journal of Law and Technology 639 (2014).

Number of pages: 40 Posted: 17 Apr 2015

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 196 (256,518)

Abstract:

18.

Maintaining Incentives for Healthcare Innovation: A Response to the FTC's Report on Follow-On Biologics

Christopher M. Holman, Maintaining Incentives for Healthcare Innovation: A Response to the FTC's Report on Follow-On Biologics, 11 MINN. J.L. SCI. & TECH. 755 (2010).

Number of pages: 46 Posted: 02 Oct 2009 Last Revised: 18 Feb 2015

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 193 (260,068)

Abstract:

19.

The Perils of Taking Property Too Far

Stanford Journal of Law, Science and Policy, Vol. 46, 2009

Number of pages: 19 Posted: 27 May 2009 Last Revised: 14 Nov 2012

Christopher Heaney, Julia Carbone, E. Richard Gold, Tania Bubela, Christopher M. Holman, Alessandra Colaianni, Tracy R. Lewis and Bob Cook-Deegan

Duke Institute for Genome Sciences & Policy, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Alberta - Faculty of Public Health, University of Missouri - Kansas City School of Law, affiliation not provided to SSRN, Duke University, Fuqua School of Business-Economics Group and Arizona State University (ASU) - School for the Future of Innovation in Society

Downloads 182 (274,044)

Abstract:

20.

Ajinomoto v. ITC, the Doctrine of Equivalents, and Biomolecule Claim Limitations at the Federal Circuit

Biotechnology Law Report, 2020

Number of pages: 25 Posted: 28 May 2020

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 180 (278,025)

Abstract:

21.

Are Engineered Genetic Sequences Copyrightable?: The U.S. Copyright Office Addresses a Matter of First Impression

35 Biotechnology Law Report 103 (2016)

Number of pages: 21 Posted: 02 Oct 2016

Christopher M. Holman, Claes Gustafsson and Andrew W. Torrance

University of Missouri - Kansas City School of Law, Independent and University of Kansas School of Law

Downloads 179 (278,025)

Citation 1

Abstract:

22.

Developments in Synthetic Biology are Altering the IP Imperatives of Biotechnology

17 Vanderbilt J. Ent. & Tech. L. 385 (2015).

Number of pages: 78 Posted: 27 Jun 2015

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 171 (289,404)

Citation 2

Abstract:

23.

The Role of Objective Indicia in Assessing the Nonobviousness of Pharmaceutical Inventions

37 Biotechnology Law Report 4 (2018)

Number of pages: 30 Posted: 08 Feb 2019

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 144 (333,828)

Abstract:

24.

Patentability Standards for Follow-On Pharmaceutical Innovation

37 BIOTECHNOLOGY LAW REPORT 131 (2018)

Number of pages: 31 Posted: 31 Jul 2018 Last Revised: 06 May 2020

Christopher M. Holman, Timo Minssen and Eric M. Solovy

University of Missouri - Kansas City School of Law, University of Copenhagen - Centre for Advanced Studies in Biomedical Innovation Law (CeBIL) - Faculty of Law and Sidley Austin LLP

Downloads 116 (393,054)

Citation 1

Abstract:

25.

Patent Eligibility Post-Myriad: A Reinvigorated Judicial Wildcard of Uncertain Effect

George Washington Law Review, Vol. 82, No. 1796, 2014

Number of pages: 36 Posted: 20 Feb 2015

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 114 (398,064)

Abstract:

26.

Caught between a Rock and a Hard Place: How Limelight Compounds the Challenges Facing Biotechnology Innovators after Mayo and Myriad

Christopher M. Holman, Caught Between a Rock and a Hard Place: How Limelight Compounds the Challenges Facing Biotechnology Innovators After Mayo and Myriad, 33 BIOTECHNOLOGY LAW REPORT 135 (2014).

Number of pages: 4 Posted: 20 Feb 2015 Last Revised: 21 Feb 2015

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 111 (405,898)

Abstract:

27.

The Critical Role of Patents in the Development, Commercialization and Utilization of Innovative Genetic Diagnostic Tests and Personalized Medicine

Boston University journal of Science and Technology Law, Vol. 21, No. 2, 2015

Number of pages: 20 Posted: 12 Feb 2016

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 109 (411,241)

Abstract:

28.

Congress Should Decline Ill-Advised Legislative Proposals Aimed at Evergreening of Pharmaceutical Patent Protection

The University of the Pacific Law Review, 2020

Number of pages: 30 Posted: 03 Jun 2020

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 105 (425,141)

Abstract:

29.

Bowman v. Monsanto Co.: A Bellwether for the Emerging Issue of Patentable Self-Replicating Technologies and Inadvertent Infringement

Missouri Law Review, Vol. 80, 2015

Number of pages: 59 Posted: 12 Feb 2016

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 103 (428,080)

Abstract:

30.

Supreme Court Asked to Consider Role of Post-Filing Evidence in Assessing Obviousness of Pharmaceutical Inventions

34 Biotechnology L. Rep. 49 (2015).

Number of pages: 4 Posted: 27 Jun 2015

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 93 (458,293)

Abstract:

31.

Charting the Contours of a Copyright Regime Optimized for Engineered Genetic Code

Oklahoma Law Review

Number of pages: 63 Posted: 04 Sep 2016

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 89 (471,049)

Citation 1

Abstract:

32.

Is the Chemical Genus Claim Really 'Dead' at the Federal Circuit?: Part II

41 BIOTECHNOLOGY LAW REPORT 58 (2022)

Number of pages: 30 Posted: 01 Mar 2023 Last Revised: 02 Mar 2023

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 83 (491,633)

Abstract:

33.

How Real is the Concern that Seed Patents Will Turn Farmers into Inadvertent Infringers?

Christopher M. Holman, How Real Is the Concern that Seed Patents Will Turn Farmers into Inadvertent Infringers?, 33 BIOTECHNOLOGY LAW REPORT 165 (2014).

Number of pages: 6 Posted: 20 Feb 2015

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 83 (491,633)

Abstract:

34.

The Enablement and Written Description Requirements Through the Lens of the Federal Circuit's Actions (As Opposed to Its Words)

41 BIOTECHNOLOGY LAW REPORT 219 (2022)

Number of pages: 26 Posted: 08 Mar 2023

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 81 (502,479)

Abstract:

35.

Book Review: Patent Ethics: Prosecution, by David Hricik & Mercedes Meyers

The IP Law Book Review, Vol. 1, No. 1, pp 40-45, June 2010

Number of pages: 7 Posted: 09 Oct 2010

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 80 (502,479)

Abstract:

36.

Amgen v. Sanofi: The Supreme Court Takes up the Enablement Requirement in the Context of Therapeutic Monoclonal Antibodies

41 BIOTECHNOLOGY LAW REPORT 269 (2022)

Number of pages: 21 Posted: 08 Mar 2023

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 78 (509,958)

Abstract:

37.

A Look at the Current Status of the CRISPR Patent Interferences Involving Broad Institute, University of California and University of Vienna, ToolGen, and Sigma-Aldrich

41 BIOTECHNOLOGY LAW REPORT 169 (2022)

Number of pages: 25 Posted: 08 Mar 2023

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 73 (529,494)

Abstract:

38.

Patent Eligibility as a Policy Lever to Regulate the Patenting of Personalized Medicine

Christopher M. Holman, Patent Eligibility as a Policy Lever to Regulate the Patenting of Personalized Medicine, book chapter in PERSPECTIVES ON PATENTABLE SUBJECT MATTER, edited by Michael Abramowicz, F. Scott Kieff and James E. Daily, Cambridge University Press (2014).

Number of pages: 32 Posted: 20 Feb 2015

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 72 (533,585)

Abstract:

39.

Do Biotech Patent Lawsuits Really 'Overwhelmingly Lose?': A Response to Our Divided Patent System

34 Biotechnology L. Rep. 59 (2015).

Number of pages: 9 Posted: 27 Jun 2015

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 69 (546,026)

Abstract:

40.

Misplaced Fears in the Battle Over Affordable Biotech Drugs

50 IDEA 565 (2010)

Number of pages: 27 Posted: 21 Mar 2015

David E. Adelman, David E. Adelman and Christopher M. Holman

University of Texas School of LawUniversity of Texas at Austin - Kay Bailey Hutchison Center for Energy, Law & Business and University of Missouri - Kansas City School of Law

Downloads 66 (559,037)

Abstract:

41.

Is the Chemical Genus Claim Really 'Dead' at the Federal Circuit?: Part I

41 BIOTECHNOLOGY LAW REPORT 4 (2022).

Number of pages: 31 Posted: 01 Mar 2023 Last Revised: 04 Mar 2023

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 62 (577,063)

Abstract:

42.

Unpredictability in Patent Law and Its Effect on Pharmaceutical Innovation

Missouri Law Review, Vol. 76, p. 645, 2011

Number of pages: 49 Posted: 21 Mar 2015

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 61 (581,646)

Abstract:

43.

Gilead Sciences Sued for Failing to Bring a Follow-on Version of Truvada to Market Sooner

Biotechnology Law Report, 2019

Number of pages: 15 Posted: 27 May 2020

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 60 (586,423)

Abstract:

44.

Nuvo v. Dr. Reddy and the Patentability of Prophetic Pharmaceutical Inventions Based on Unexplained Inventive Insight

Biotechnology Law Report, 2019

Number of pages: 13 Posted: 27 May 2020

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 53 (621,687)

Abstract:

45.

Helsinn v. Teva: Lingering Ambiguity after the U.S. Supreme Court Holds the AIA Did Not Alter the On-Sale Bar to Patentability

Biotechnology Law Report, 2019

Number of pages: 23 Posted: 27 May 2020

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 47 (654,954)

Abstract:

46.

The Lilly Written Description Requirement: A Doctrinal Wildcard of Uncertain Effect

Research Handbook on Patent Law & Theory (2nd Edition), ISBN: 978-1-78536-411-2, Edward Elgar, 2019

Number of pages: 33 Posted: 02 Jun 2020

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 46 (660,846)

Abstract:

47.

The Renewable Fuel Standard Reimagined: Clearing a Path for Truly Advanced Biofuels

86 UMKC L. Rev. 805 (2018)

Number of pages: 50 Posted: 02 Jun 2020

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 45 (666,705)

Abstract:

48.

Eli Lilly v. Teva: Generic Companies Infringe under Akamai IV in Case of Divided Infringement

36 BIOTECHNOLOGY LAW REPORT 31 (2017)

Number of pages: 7 Posted: 17 Aug 2020

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 44 (672,647)

Abstract:

49.

Praxair v. Mallinckrodt: An Expanded Interpretation of the Printed Matter Doctrine with Important Implications for Biotechnology

37 BIOTECHNOLOGY LAW REPORT 188 (2018)

Number of pages: 17 Posted: 23 Oct 2020

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 42 (685,044)

Abstract:

50.

A Fractured International Response to CRISPR-Enabled Gene Editing of Agricultural Products

38 Biotechnology Law Report 3 (2019).

Number of pages: 54 Posted: 22 Apr 2020

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 41 (691,371)

Abstract:

51.

Branded Drug Companies are Successfully Asserting the Doctrine of Equivalents in Hatch-Waxman Litigation

40 BIOTECHNOLOGY LAW REPORT 72 (2021)

Number of pages: 34 Posted: 25 Mar 2022

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 36 (724,936)

Abstract:

52.

Vanda v. West-Ward Pharmaceuticals: Good News for the Patent Eligibility of Diagnostics and Personalized Medicine, with Some Important Caveats

37 BIOTECHNOLOGY LAW REPORT 117 (2018)

Number of pages: 9 Posted: 23 Oct 2020

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 35 (731,921)

Abstract:

53.

The Role of Patent Eligibility in Policing Claim Scope

1 IP Theory 56 (2011)

Number of pages: 15 Posted: 21 Mar 2015

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 35 (731,921)

Abstract:

54.

Congress Considering Legislation Aimed at Increasing Competition in Pharmaceuticals

Biotechnology Law Report, 2019

Number of pages: 15 Posted: 27 May 2020

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 33 (753,684)

Abstract:

55.

Congress Considering Legislation Intended to Reverse the Recent Trend toward Devaluation of the U.S. Patent Right

37 BIOTECHNOLOGY LAW REPORT 243 (2018)

Number of pages: 12 Posted: 23 Oct 2020

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 31 (761,302)

Abstract:

56.

Recent PTO Guidance Charts a New Course Through the Patent Eligibility Quagmire

Biotechnology Law Report, 2019

Number of pages: 13 Posted: 27 May 2020

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 30 (769,056)

Abstract:

57.

The Supreme Court’s Devaluation of U.S. Patents

36 BIOTECHNOLOGY LAW REPORT 151 (2017)

Number of pages: 16 Posted: 21 Oct 2020

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 29 (776,842)

Abstract:

58.

The Federal Circuit Continues to Grapple with the Question of Patent Eligibility for Diagnostic Methods

40 BIOTECHNOLOGY LAW REPORT 151 (2021)

Number of pages: 37 Posted: 25 Mar 2022

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 28 (784,491)

Abstract:

59.

A Biotechnology-Centric Look at Fee Shifting in Patent Litigation Post-Octane Fitness

36 BIOTECHNOLOGY LAW REPORT 81 (2017)

Number of pages: 4 Posted: 21 Oct 2020

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 28 (792,484)

Abstract:

60.

The Mayo Framework Is Bad for Your Health

23 George Mason Law Review 901 (2016)

Number of pages: 40 Posted: 02 Jun 2020

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 27 (800,557)

Abstract:

61.

Government Involvement in Pharmaceutical Development Can Come Back to Haunt a Drug Company

40 BIOTECHNOLOGY LAW REPORT 4 (2021)

Number of pages: 26 Posted: 25 Mar 2022

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 26 (800,557)

Abstract:

62.

FDA’s Efforts to Tame the 'Wild West' of Regenerative Medicine

36 BIOTECHNOLOGY LAW REPORT 217 (2017)

Number of pages: 6 Posted: 21 Oct 2020

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 24 (817,393)

Abstract:

63.

District Court’s Interpretation of Mayo in Arioso Diagnostics Does Not Bode Well for Patent Eligibility of Diagnostics and Personalized Medicine

33 BIOTECHNOLOGY LAW REPORT 46 (2014)

Number of pages: 3 Posted: 01 May 2023

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 22 (834,828)

Abstract:

64.

The Broad Institute Scores Another Victory in Its Battle with the University of California over the Patenting of CRISPR

41 BIOTECHNOLOGY LAW REPORT 122 (2022)

Number of pages: 24 Posted: 08 Mar 2023

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 22 (834,828)

Abstract:

65.

AbbVie Hopes to Maintain Humira Exclusivity Through Secondary Patents and Regulatory Barriers to Entry

36 BIOTECHNOLOGY LAW REPORT 9 (2017)

Number of pages: 8 Posted: 21 Apr 2023

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 21 (843,701)

Abstract:

66.

In Minerva v. Hologic, the U.S. Supreme Court Reins in the Equitable Doctrine of Assignor Estoppel

40 BIOTECHNOLOGY LAW REPORT 294 (2021)

Number of pages: 28 Posted: 25 Mar 2022

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 19 (861,984)

Abstract:

67.

In re Huping Hu: Quantum Entanglement, Medical Innovation, and Patentability on the Scientific 'Fringe'

40 BIOTECHNOLOGY LAW REPORT 222 (2021)

Number of pages: 23 Posted: 25 Mar 2022

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 19 (861,984)

Abstract:

68.

The Federal Circuit’s Ongoing Expansion of Obviousness-Type Double Patenting Creates Patent Prosecution Pitfalls

33 BIOTECHNOLOGY LAW REPORT 94 (2014)

Number of pages: 4 Posted: 27 Apr 2023

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 17 (890,342)

Abstract:

69.

Trade Secret Law: An Increasingly Important Form of IP for Biotechnology

35 BIOTECHNOLOGY LAW REPORT 45 (2016)

Number of pages: 10 Posted: 27 Apr 2023

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 15 (899,980)

Abstract:

70.

For Monoclonal Antibodies, Compliance with the Written Description Requirement Has Become a Moving Target

36 BIOTECHNOLOGY LAW REPORT 273 (2017)

Number of pages: 11 Posted: 06 Mar 2023

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 11 (939,114)

Abstract:

71.

Acorda Therapeutics and the Role of Blocking Patents in Assessing Objective Indicia of Nonobviousness in the Pharmaceutical Arts

37 BIOTECHNOLOGY LAW REPORT 305 (2018)

Number of pages: 9 Posted: 06 Mar 2023

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 10 (948,838)

Abstract:

72.

In Myriad the Supreme Court Has, Once Again, Increased the Uncertainty of US Patent Law

32 BIOTECHNOLOGY LAW REPORT 289 (2013).

Number of pages: 5 Posted: 01 May 2023

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 9 (967,234)

Abstract:

73.

Status Update: Implementation of the Patent Dispute Resolution Provisions of the Biologics Price Competition and Innovation Act

34 BIOTECHNOLOGY LAW REPORT 247 (2015)

Number of pages: 5 Posted: 27 Apr 2023

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 9 (967,234)

Abstract:

74.

Cuozzo v. Lee: Supreme Court to Decide Its First Inter Partes Review Case

35 BIOTECHNOLOGY LAW REPORT 3 (2016)

Number of pages: 6 Posted: 27 Apr 2023

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 9 (958,076)

Abstract:

75.

District Court's Interpretation of Mayo in Ariosa Diagnostics Does Not Bode Well for Patent Eligibility of Diagnostics and Personalized Medicine

33 BIOTECHNOLOGY LAW REPORT 46 (2014)

Number of pages: 3 Posted: 01 May 2023

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 8 (967,234)

Abstract:

76.

Status Update: Implementation of Various Non-patent Aspects of the Biologics Price Competition and Innovation Act of 2009

34 BIOTECHNOLOGY LAW REPORT 189 (2015)

Number of pages: 8 Posted: 27 Apr 2023

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 8 (976,124)

Abstract:

77.

Mayo Update: Some Reason for Guarded Optimism

35 BIOTECHNOLOGY LAW REPORT 175 (2016)

Number of pages: 11 Posted: 19 Apr 2023

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 8 (976,124)

Abstract:

78.

The Medicines Company v. Hospira: When Does Outsourcing Drug Manufacture to a Third-Party Contractor Trigger an On-Sale Bar to Patentability?

35 BIOTECHNOLOGY LAW REPORT 129 (2016)

Number of pages: 8 Posted: 19 Apr 2023

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 8 (967,234)

Abstract:

79.

Enablement Invoked as a ‘Super-Written Description Requirement’ to Overturn $2.5 Billion Jury Verdict

37 BIOTECHNOLOGY LAW REPORT 63 (2018)

Number of pages: 5 Posted: 01 Mar 2023

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 8 (967,234)

Abstract:

80.

A Proliferation of Legislation Targeting Genetically Modified Crops

34 BIOTECHNOLOGY LAW REPORT 207 (2015)

Number of pages: 6 Posted: 27 Apr 2023

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 7 (976,124)

Abstract:

81.

In Life Technologies v. Promega the Supreme Court Leaves Unresolved Many Questions Regarding the Potential for Infringement under 35 U.S. 271(f)(1)

36 BIOTECHNOLOGY LAW REPORT 42 (2017)

Number of pages: 9 Posted: 21 Apr 2023

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 7 (976,124)

Abstract:

82.

Two Recent U.S. Reports Identify Shortcomings in USDA’s Regulation of GE Crops

35 BIOTECHNOLOGY LAW REPORT 83 (2016)

Number of pages: 5 Posted: 27 Apr 2023

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 6 (984,442)

Abstract:

83.

Setbacks in Implementing the Renewable Fuel Standard Lead to Calls for Reform

35 BIOTECHNOLOGY LAW REPORT 249 (2016)

Number of pages: 9 Posted: 19 Apr 2023

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 6 (992,395)

Abstract:

84.

The Biotechnology Industry Organization (BIO) and Pharmaceutical Research and Manufacturers of America (PhRMA) Seek En Banc Review of Ariosa Diagnostics v. Sequenom

34 BIOTECHNOLOGY LAW REPORT 169 (2015)

Number of pages: 2 Posted: 27 Apr 2023

Christopher M. Holman

University of Missouri - Kansas City School of Law

Downloads 5 (992,395)

Abstract:

85.

Trend in Human Gene Patent Litigation

Science 322:198-99 (2008)

Posted: 21 Mar 2015

Christopher M. Holman

University of Missouri - Kansas City School of Law

Abstract:

86.

Patent Border Wars: Defining the Boundary between Scientific Discoveries and Patentable Inventions

Trends in Biotechnology, Vol. 25, pp. 539-543, 2007

Posted: 11 Feb 2008

Christopher M. Holman

University of Missouri - Kansas City School of Law

Abstract:

87.

Clearing a Path Through the Patent Thicket

Cell, Vol. 125, pp. 629-633, 2006

Posted: 18 Oct 2006 Last Revised: 17 May 2014

Christopher M. Holman

University of Missouri - Kansas City School of Law

Christopher M. Holman

University of Missouri - Kansas City School of Law

Professor of Law

87

Top 6,936

10,889

Top 27,502

17

20

Scholarly Papers (87)

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract:

Abstract: